Ibrance is indicated for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.1

IBRANCE® (palbociclib)

Useful Resources

STRENGTH FROM…

CDK = cyclin-dependent kinase ;HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; RCT = randomised controlled trial.

References

  1. IBRANCE® (Palbociclib) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12240. Accessed September 17, 2021.
  2. Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729.
  3. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
  4. Turner NC, et al. SABCS 2016; poster P4-22-06.
All rights reserved. Date of preparation: June 2020 PP-IBR-GLB-0254

​​​​​​​Intended for Healthcare Professionals only.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.